Back A A A Font Size Receive E-mail Alerts Press Releases

MicroPort® Endovascular's "Hercules®" Trademark Granted Entry into the List of the Third Batch of Major Protected Trademarks of Shanghai Municipality


Shanghai, China - The Shanghai Municipal Administration of Market Regulation recently published the List of the Third Batch of Major Protected Trademarks of Shanghai Municipality ("the List"). The "Hercules®" trademark of Shanghai MicroPort Endovascular MedTech Co., Ltd. ("MicroPort® Endovascular") was granted the entry into the List and rated as one of the third batch of Major Protected Trademarks of Shanghai Municipality.
The Major Protected Trademarks of Shanghai refers to the registered trademarks which enjoy high visibility and strong market influence, are prone to be the objects of infringement and counterfeiting, and hence need stronger protection. The Shanghai Municipality compiled the list of the Major Protected Trademarks in a bid to enhance the crackdown on the infringement of the exclusive right to use the Major Protected Trademarks, to establish and continuously improve the long-term oversight mechanism for the protection of the Major Protected Trademarks, and to create favorable environment for the protection of intellectual property. In 2018, the trademarks of "微创®" and "MicroPort®" were already granted the entry into the List of the First Batch of Major Protected Trademarks of Shanghai Municipality and rated as two of the first batch of Major Protected Trademarks of Shanghai Municipality.
The "Hercules®" trademark stems from the name of a hero and god in classical mythology, who is embodies strength. The stent graft and delivery system products named after Hercules® are the core products independently developed by MicroPort® Endovascular, and have also been rated as one of the First Batch of Independently Innovated Products of Shanghai Municipality. The products include Hercules® Thoracic Stent-Graft System and Hercules® Abdominal Aortic Stent-Graft System, which are the first of their likes in China and used in the treatment of thoracic and abdominal aortic aneurysmal diseases. They have demonstrated outstanding clinical performance and saved the lives of nearly 100,000 patients suffering from artic diseases since their launches.
MicroPort® Endovascular always thinks highly of trademark protection and branding. After years of continuous publicity and maintenance, the "Hercules®" trademark is enjoying extremely high visibility and reputation both domestically and abroad. In 2016, Hercules® Stent Graft and Delivery System was awarded the title of Famous Shanghai Product. The entry into the List will give MicroPort® Endovascular access to the collaborative protection mechanism built by the government, which will play a positive role in the ensuing protection and rights issues, especially those happening outside of Shanghai, that involve the "Hercules®" trademark.
According to the Administrative Measures for the List of Major Protected Trademarks of Shanghai Municipality (Trial), Shanghai Municipal Administration of Industry and Commerce and the district-level market regulatory authorities will reinforce the cooperation with the judicial departments, the provincial industry and commerce (market regulatory) authorities outside of Shanghai, Shanghai Municipal Commission of Economy and Informization, Shanghai Municipal Commission of Commerce, and the Shanghai-based central government authorities such as the Customs, and build a cross-function, cross-region coordinative protection mechanism. By means of such mechanism, the clues of infringement of the rights of the Major Protected Trademarks in the List will be timely gathered in the areas outside of Shanghai, and proactive cross-region coordinative protection of the rights of the Major Protected Trademarks will be carried out. In addition, full use of the coordinative network will be made for the protection of the trademark rights in the Yangtze River Delta region to enhance the protection of the rights of the Major Protected Trademarks included in the List.

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 12 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Cardiac Rhythm Management, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to:

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 1998-2019 MicroPort Scientific Corporation

Leanne Li
Board Secretary and Vice President of Corporate General Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600-6953


[Prev]:MicroPort® Orthopedics Aspiration Medial Stability Total Knee Replacement System – PS Type Implant Obtains Approval in China
[Next]:Firehawk® and Rega® Family Implantable Pacemakers Make the List of Health China (2018) • Top 10 Medical Devices